2022

1. Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

   Cancer immunology research, Vol. 10, Núm. 4, pp. 498-511

2. Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

   iScience, Vol. 25, Núm. 9